The genetic polymorphism of Equilibrative Nucleoside Transporter 1 [ENT1] is involved in ribavirin cellular uptake
and it could positively enhance antiviral treatment response. The liver transplant setting offers the unique opportunity to
selectively observe the effect(s) of the donor liver ENT1 gene on HCV treatment outcome. We aimed at studying donor
polymorphism of ENT1 and HCV therapy outcome in transplanted patients. The role of ribavirin plasma concentration
was evaluated. 39 patients after HCV recurrence were included. Genotyping of donor ENT1 and of IL-28B was performed
in donor liver samples by RNA PCR. Allelic frequencies of liver ENT1 were: AA 43.6%; AG 28.2%; GG 28.2%. GG
genotype was associated with rapid [RR=8; 95% CI 1.6-38; p=0.01] and sustained virological response [RR=9.5; 95%
CI 1.6-53; p=0.01]. In multivariate analysis, GG genotype and a ribavirin plasma concentration >2.0 ng/mL at week 12
were independently associated with sustained virological response. In conclusion, the genetic polymorphism of ENT
influences treatment response and a pre-treatment determination of its activity could help to predict treatment response
in HCV patients